学术兼职： 1. 私立纽约大学兼职副教授 2. 英国南汉普顿大学southampton statistical sciences research institute, associate. 3. steering committee, multi-purpose prevention technologies initiatives 4. guideline development group, 世卫组织sexual, reproductive health and rights 5. 中国性病艾滋病防治协会常务委员 6. frontiers in immunology, associate editor 7. frontiers in microbiology, review editor
|
|
吴稚伟1982年本科毕业于南京大学；1991年获英国爱丁堡大学博士学位；1990-1997年在美国私立纽约大学接受博士后训练，1997-2006分别在洛克菲勒大学和宾夕法尼亚大学leon levy研究中心担任助理教授和高级研究员职位。2006年应南京大学聘请，负责组建公共健康医学中心。现任南京大学教授，博导，公共健康医学中心主任，南京大学生命分析化学国家重点实验室副主任。兼任私立纽约大学客座副教授（adjunct associate professor）和英国南汉普顿大学社会科学和生物统计学院associate member。 吴稚伟长期从事病毒感染和免疫学，疫苗和抗病毒药物的研究和开发。主要的研究兴趣有如下几方面：（1）细胞外囊泡（sev）对病毒的病理、宿主抗病毒免疫调控和病毒传播的影响及作用的分子机制；利用胞外囊泡作为病毒感染治疗性药物的靶向递送载体（2）rna病毒与宿主细胞的相互作用，对宿主免疫系统干扰、调控以及对病毒致病分子机制的研究（3）利用纳米抗体诱导和发现的技术平台，研究和开发高效抑制病毒复制的治疗用纳米单克隆抗体，并通过人源化、纳米抗体工程化构建高生物学效价、内体长效纳米抗体，并研发不同的纳米抗体药物递送途径（4）利用纳米抗体的高亲和力特点，研制用于特异性、高灵敏纳米抗体快速免疫诊断试剂，特别是用于临场检测的poct装置。 吴稚伟曾担任艾滋病疫苗基础研究专项（973项目）课题负责人，国家十一五，十二五和十三五传染病重大专项负责人，承担对艾滋病生物预防，疫苗和高致病性病毒感染（如sftsv, ev71, sars-cov2，mers-cov, ebov和hiv-1等）的治疗性抗体和诊断技术研究。吴稚伟同时高度关注公共卫生及疾病干预, 在若干国际组织中任职，如美国mpti steering committee委员, 在世界卫生组织（who） microbicides regional temporary advisory 和who guidelines development group (voting member)担任专家委员, 以及担任frontiers in immunology副主编，frontiers in pharmacology评审编辑（review editor）。 |
yuxuan fu, li zhang, fang zhang, ting tang, chunhong feng, yu jin, zhiwei wu*.exosome-mediated mir-146a transfer suppresses type i interferon response and facilitates ev71 infection. plos pathogen (2017). 13(9):e1006611. . peixin song, nan zheng, yong liu, chen tian, xilin wu, xiaohua ma, deyan chen, xue zou, guiyang wang, huanru wang, yongyang zhang, sufang lu, chao wu, zhiwei wu*. deficient humoral response and disrupted b cell immunity are associated with fatal sftsv infection. nature communications(2018) 9:3328/doi: 10.1038/s41467-018-05746-9. xilin wu, yanlei li,xiaohua ma, linjing zhu, bilian huang, nan zheng, shijie xu, waqas nawaz, zhiwei wu*. development of a potent neutralizing nanobody as therapeutics against sftsv infection. jci insight. 2020; 5(13):e136855. . xue zou, meng yuan, yutong zhang, nan zheng*and zhiwei wu*. extracellular vesicles containing host restriction factor ifitm3 inhibited zika virus infection of fetuses in pregnant mice through trans-placenta delivery. molecular therapy vol. 29 no.1 jan. 2021. pp 1-15. waqas nawaz, shijie xu, yanlei li, bilian huang, xilin wu*, zhiwei wu*. nanotech and immunoengineering: how nanotech can boost car-t therapy. acta biomaterialia 109 (2020) 21-36. frederik j. verweij, leonora balaj, chantal boulanger, david rf carter, ewaldus b compeer, gisela d’angelo g, samir el andaloussi, jacky g. goetz, julia groß, vincent hyenne, eva-maria krämer-albers a, charles lai, xavier loyer, alex marki, stefan momma, esther nolte ‘t hoen, michiel d pegtel, hector peinado, graça raposo, kirsi rilla, hidetoshi tahara, clotilde théry, martin van royen, roosmarijn vandenbroecke, ann wehman, kenneth witwer, zhiwei wu, richard wubbolts, guillaume van niel. the power of imaging to understand ev biology in vivo. nature methods (2021). . waqas nawaz, bilian huang, shijie xu,yanlei li, linjing zhu, hu yiqiao, zhiwei wu*, xilin wu*. aav-mediated in vivo car gene therapy for targeting human t-cell leukemia. blood cancer journal (2021) 11:119; . shijie xu, na jiang, waqas nawaz, bingxin liu, fang zhang, ye liu, xilin wu* and zhiwei wu*. infection of humanized mice with a novel phlebovirus presented pathogenic features of sever fever with thrombocytopenia syndrome. plos pathog (2021) 17(5): e1009587. https:// doi.org/10.1371/journal.ppat.1009587. li zhang, yuxuan fu, rui zhang, yajie guan, na jiang, nan zheng*, zhiwei wu*. nonstructural protein nss hampers cellular antiviral response through lsm14a during severe fever with thrombocytopenia syndrome virus infection. j immunol.2021, 207: 1-12. xilin wu, lin cheng, ming fu, bilian huang, yalan liu, linjing zhu, shijie xu, haixia shi, doudou zhang, huanyun yuan, waqas nawaz, ping yang, qinxue hu, zhiwei wu*.potent bispecific nanobody provides in vivo protection against sars-cov-2 via intranasal administration. cell reports (2021)(in press).
|
